Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: JGoren who wrote (915)	1/18/1999 12:23:00 PM
From: Dan Spillane	Respond to of 2539

I am questioning the timing of those papers, and the published accreditation, relative to the FDA approval date of Celebrex. To wit, both were published right after the approval. I'm sure those articles take many months. I never said "the University" wanted to stir up trouble. Any "hidden" motives, if present, would likely be personal and/or competitively-driven. As an example of a personal motive, these guys could trade options on stocks as they relate to the studies. A competitive motive might be desire for funding on other projects, sponsored by another drug company. Not saying they do this, but I do question why they re-hashed the study to come out with the second article with the "catchy" title.